Sep 29 2008
Zecotek Photonics Inc. today announced that the Canadian Patent Office has issued Notice of Allowance to Zecotek Imaging Systems Singapore Pte. Ltd., a wholly-owned subsidiary, for its LFS scintillation material. This application is identical to the LFS scintillation applications that have been issued or allowed in the U.S., Russia, China, Europe and Japan.
"Receiving the notice of allowance from the Canadian Patent Office is an important step in protecting our intellectual property and it offers another level of protection for our intellectual property across North America," said Dr. A. F. Zerrouk, Chairman and CEO of Zecotek. "Due to our work with the University of Washington and with leading medical equipment manufacturers, our LFS scintillation material is now widely recognized as an important new material for enhancing the performance of a wide range of imaging devices, and in particular, for its impact with next generation Positron Emission Tomography (PET) medical imaging."
Zecotek has developed and patented a new class of advanced materials targeted at the next-generation of PET, PET-CT and PET-MRI medical imaging scanners. When combined with Zecotek's MAPD solid-state photo detectors, the new scintillation materials allows for medical imaging devices to have higher resolution, enhanced diagnosis, improved patient outcomes, faster patient throughput and lower unit costs.
Other medical applications for LFS are in micro-PET detectors, widely used in drug research, and in gamma cameras used for breast and prostate examinations. Non-medical applications include gamma ray detector systems for homeland security, geological surveying, materials analysis, high energy physics and nuclear stockpile monitoring.